BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 37796807)

  • 1. Multigene panel next generation sequencing in metastatic colorectal cancer in an Australian population.
    Nindra U; Pal A; Lea V; Lim SH; Wilkinson K; Asghari R; Roberts TL; Becker TM; Farzin M; Rutland T; Lee M; MacKenzie S; Ng W; Wang B; Lee CS; Chua W
    PLoS One; 2023; 18(10):e0292087. PubMed ID: 37796807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of multigene panel next-generation sequencing in routine clinical practice for identifying genomic alterations in newly diagnosed metastatic nonsmall cell lung cancer.
    Nindra U; Pal A; Bray V; Yip PY; Tognela A; Roberts TL; Becker TM; Williamson J; Farzin M; Li JJ; Lea V; Hagelamin A; Ng W; Wang B; Lee CS; Chua W
    Intern Med J; 2024 Apr; 54(4):596-601. PubMed ID: 37713593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomically matched therapy in refractory colorectal cancer according to ESMO Scale for Clinical Actionability of Molecular Targets: experience of a comprehensive cancer centre network.
    Mulet Margalef N; Castillo C; Mosteiro M; Pérez X; Aguilar S; Ruíz-Pace F; Gil M; Cuadra C; Ruffinelli JC; Martínez M; Losa F; Soler G; Teulé À; Castany R; Gallego R; Ruíz A; Garralda E; Élez E; Vivancos A; Tabernero J; Salazar R; Dienstmann R; Santos Vivas C
    Mol Oncol; 2023 Sep; 17(9):1908-1916. PubMed ID: 37097008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive molecular profiling of Taiwanese breast cancers revealed potential therapeutic targets: prevalence of actionable mutations among 380 targeted sequencing analyses.
    Huang CC; Tsai YF; Liu CY; Chao TC; Lien PJ; Lin YS; Feng CJ; Chiu JH; Hsu CY; Tseng LM
    BMC Cancer; 2021 Feb; 21(1):199. PubMed ID: 33632156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performance validation of an amplicon-based targeted next-generation sequencing assay and mutation profiling of 648 Chinese colorectal cancer patients.
    Wang Y; Liu H; Hou Y; Zhou X; Liang L; Zhang Z; Shi H; Xu S; Hu P; Zheng Z; Liu R; Tang T; Ye F; Liang Z; Bu H
    Virchows Arch; 2018 Jun; 472(6):959-968. PubMed ID: 29705968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic specificity study using next-generation sequencing (NGS) of peritoneal metastatic colorectal cancer compared to primary colorectal cancer.
    Lee S; Shin W; Park DG; Namgung H
    Genes Genomics; 2024 Mar; 46(3):289-302. PubMed ID: 38316717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-World Data and Clinical Implications of Next-Generation Sequencing (NGS)-Based Analysis in Metastatic Breast Cancer Patients.
    Canino F; Tornincasa A; Bettelli S; Manfredini S; Barbolini M; Moscetti L; Omarini C; Toss A; Tamburrano F; Antonelli G; Baglio F; Belluzzi L; Martinelli G; Natalizio S; Ponzoni O; Dominici M; Piacentini F
    Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fecal gene detection based on next generation sequencing for colorectal cancer diagnosis.
    He SY; Li YC; Wang Y; Peng HL; Zhou CL; Zhang CM; Chen SL; Yin JF; Lin M
    World J Gastroenterol; 2022 Jul; 28(25):2920-2936. PubMed ID: 35978873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy.
    Vidal J; Bellosillo B; Santos Vivas C; García-Alfonso P; Carrato A; Cano MT; García-Carbonero R; Élez E; Losa F; Massutí B; Valladares-Ayerbes M; Viéitez JM; Manzano JL; Azuara D; Gallego J; Pairet S; Capellá G; Salazar R; Tabernero J; Aranda E; Montagut C
    Ann Oncol; 2019 Mar; 30(3):439-446. PubMed ID: 30689692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current practice of genomic profiling of patients with advanced solid tumours in Italy: the Italian Register of Actionable Mutations (RATIONAL) study.
    Normanno N; De Luca A; Abate RE; Morabito A; Milella M; Tabbò F; Curigliano G; Masini C; Marchetti P; Pruneri G; Guarneri V; Frassineti GL; Fasola G; Adamo V; Daniele B; Berardi R; Feroce F; Maiello E; Pinto C
    Eur J Cancer; 2023 Jul; 187():174-184. PubMed ID: 37167765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Guardant360 Circulating Tumor DNA Assay Is Concordant with FoundationOne Next-Generation Sequencing in Detecting Actionable Driver Mutations in Anti-EGFR Naive Metastatic Colorectal Cancer.
    Gupta R; Othman T; Chen C; Sandhu J; Ouyang C; Fakih M
    Oncologist; 2020 Mar; 25(3):235-243. PubMed ID: 32162812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spatio-temporal mutation profiles of case-matched colorectal carcinomas and their metastases reveal unique de novo mutations in metachronous lung metastases by targeted next generation sequencing.
    Kovaleva V; Geissler AL; Lutz L; Fritsch R; Makowiec F; Wiesemann S; Hopt UT; Passlick B; Werner M; Lassmann S
    Mol Cancer; 2016 Oct; 15(1):63. PubMed ID: 27756406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical implications of prospective genomic profiling of metastatic breast cancer patients.
    van Geelen CT; Savas P; Teo ZL; Luen SJ; Weng CF; Ko YA; Kuykhoven KS; Caramia F; Salgado R; Francis PA; Dawson SJ; Fox SB; Fellowes A; Loi S
    Breast Cancer Res; 2020 Aug; 22(1):91. PubMed ID: 32811538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic landscape of colorectal cancer in Japan: clinical implications of comprehensive genomic sequencing for precision medicine.
    Nagahashi M; Wakai T; Shimada Y; Ichikawa H; Kameyama H; Kobayashi T; Sakata J; Yagi R; Sato N; Kitagawa Y; Uetake H; Yoshida K; Oki E; Kudo SE; Izutsu H; Kodama K; Nakada M; Tse J; Russell M; Heyer J; Powers W; Sun R; Ring JE; Takabe K; Protopopov A; Ling Y; Okuda S; Lyle S
    Genome Med; 2016 Dec; 8(1):136. PubMed ID: 28007036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rare RAS Mutations in Metastatic Colorectal Cancer Detected During Routine RAS Genotyping Using Next Generation Sequencing.
    Harlé A; Filhine-Tresarrieu P; Husson M; Boidot R; Rouyer M; Dubois C; Leroux A; Merlin JL
    Target Oncol; 2016 Jun; 11(3):363-70. PubMed ID: 26661077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
    Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
    Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).
    Condorelli R; Mosele F; Verret B; Bachelot T; Bedard PL; Cortes J; Hyman DM; Juric D; Krop I; Bieche I; Saura C; Sotiriou C; Cardoso F; Loibl S; Andre F; Turner NC
    Ann Oncol; 2019 Mar; 30(3):365-373. PubMed ID: 30715161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms.
    Mackenzie R; Kommoss S; Winterhoff BJ; Kipp BR; Garcia JJ; Voss J; Halling K; Karnezis A; Senz J; Yang W; Prigge ES; Reuschenbach M; Doeberitz MV; Gilks BC; Huntsman DG; Bakkum-Gamez J; McAlpine JN; Anglesio MS
    BMC Cancer; 2015 May; 15():415. PubMed ID: 25986173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of KRAS, NRAS and BRAF hotspot mutations detection for patients with metastatic colorectal cancer using direct DNA pipetting in a fully-automated platform and Next-Generation Sequencing for laboratory workflow optimisation.
    Gilson P; Franczak C; Dubouis L; Husson M; Rouyer M; Demange J; Perceau M; Leroux A; Merlin JL; Harlé A
    PLoS One; 2019; 14(7):e0219204. PubMed ID: 31265477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study.
    Antoniotti C; Korn WM; Marmorino F; Rossini D; Lonardi S; Masi G; Randon G; Conca V; Boccaccino A; Tomasello G; Passardi A; Swensen J; Ugolini C; Oberley M; Tamburini E; Casagrande M; Domenyuk V; Fontanini G; Giordano M; Abraham J; Spetzler D; Falcone A; Lenz HJ; Cremolini C
    Eur J Cancer; 2021 Sep; 155():73-84. PubMed ID: 34365081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.